Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPH7854 Phase 1 Study in Healthy Subjects
NCT06483373Phase 1Recruiting
- Sponsor
- Shanghai Pharmaceuticals Holding Co Ltd
- Start
- May 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of SPH7854 in inflammatory bowel disease (IBD) (2 arms), sponsored by Shanghai Pharmaceuticals Holding Co Ltd. Primary endpoint: Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events at 2 years. Started May 2024; status: recruiting.
02
Drugs
SPH7854
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT06483373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06483373.